Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils.

Abstract The effect of the selective COX-2 inhibitor, etodolac, on Helicobacter pylori ( Hp )-associated stomach carcinogenesis was investigated in Mongolian gerbils (MGs). Hp -infected MGs were fed for 23 weeks with drinking water containing 10 ppm N -methyl- N -nitrosourea. They were then switched to distilled water and placed on a diet containing 5–30 mg/kg/day etodolac for 30 weeks. We found that etodolac dose-dependently inhibited the development of gastric cancer, and no cancer was detected at a dose of 30 mg/kg/day. Etodolac did not affect the extent of inflammatory cell infiltration or oxidative DNA damage, but it significantly inhibited mucosal cell proliferation and dose-dependently repressed the development of intestinal metaplasia in the stomachs of Hp -infected MGs. These results suggest that COX-2 is a key molecule in inflammation-mediated stomach carcinogenesis and that chemoprevention of stomach cancer should be possible by controlling COX-2 expression or activity.